(TXG) 10x Genomics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TXG) 10x Genomics, Inc. Complete Analysis Pack
Actionable Strategy Starts Here
This 10x Genomics, Inc. BCG Matrix helps you see how the company’s products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Visium HD spatial gene expression
Visium HD is 10x Genomics’ higher-resolution spatial transcriptomics system, with 2 µm capture areas for whole-transcriptome tissue mapping. It fits the Stars box: high growth and rising adoption in a spatial biology market that is still expanding fast. Because the category is early, sales support and assay workflow help still matter.
Xenium In Situ spatial imaging
Xenium In Situ is 10x Genomics’ in situ spatial platform for single-cell and subcellular resolution, and it is a Star because adoption is expanding in both academia and biopharma. Spatial biology remains one of the fastest-growing areas in the portfolio, with use cases tied to discovery, translational research, and biomarker work. In 10x Genomics’ 2024 filings, the company reported $624.8 million in revenue, with continued mix shift toward higher-value spatial tools.
GEM-X Single Cell 3' Gene Expression
GEM-X Single Cell 3' Gene Expression is a Star for 10x Genomics, Inc. because it is the newer chemistry that lifts throughput and sensitivity versus older Chromium workflows. It refreshes the core single-cell franchise in a new product cycle, so it behaves like a growth engine, not a mature line. As adoption rises in 2025, it should help pull consumable demand and keep 10x's single-cell platform relevant.
GEM-X Multiome ATAC + Gene Expression
GEM-X Multiome ATAC + Gene Expression is a strong Star because it pairs chromatin accessibility and gene expression in one run, giving researchers 2 data layers from 1 cell prep. Single-cell multiomics is a premium, fast-growing niche, and it helps 10x Genomics, Inc. raise revenue per run while deepening platform lock-in.
- 2-in-1 assay, higher sample value
- Premium multiomic demand supports growth
- More data per run lifts spend
- Workflow ties users to 10x
Visium CytAssist-enabled FFPE workflows
Visium CytAssist-enabled FFPE workflows fit a Star because they open spatial analysis in FFPE, the dominant archival tissue type in translational research. The upside is strong, since FFPE links directly to large biobank and pathology archives, but market adoption still needs user education and workflow expansion. 10x Genomics reported 2025 revenue of $608.0 million, showing the platform still has real commercial scale.
- FFPE unlocks archived tissue access.
- Large research base supports growth.
- Adoption still needs education.
- Commercial scale is already proven.
10x Genomics’ Star Products Are Driving Growth
10x Genomics’ Stars are led by Visium HD and Xenium In Situ, where spatial biology demand is still expanding and adoption is rising in academia and biopharma. GEM-X Single Cell 3' and GEM-X Multiome also fit the Stars box because they refresh the core single-cell franchise with higher throughput and richer data per run. 10x Genomics reported 2025 revenue of $608.0 million, showing the platform already has scale.
| Star | Why it fits |
|---|---|
| Visium HD | High-growth spatial transcriptomics |
| Xenium In Situ | Rising single-cell spatial adoption |
| GEM-X Single Cell 3' | New cycle boosts throughput |
| GEM-X Multiome | Premium 2-layer assay |
What is included in the product
Detailed Word Document
10x Genomics BCG Matrix maps products by growth and share to guide invest, hold, or divest decisions.
Editable Excel File
One-page BCG Matrix for 10x Genomics, Inc. to quickly spot growth bets and underperformers
Reference Sources
Provides a traceable source trail for 10x Genomics, boosting credibility and helping investors verify key assumptions fast.
Cash Cows
Chromium Controller installed base
Chromium Controller is the legacy workhorse behind 10x Genomics, Inc.'s Chromium assays, so each installed unit keeps driving repeat consumable sales with little extra selling cost. That installed base supports steady, high-margin cash flow and makes the business less dependent on new instrument placements. In BCG terms, it fits a Cash Cow because revenue comes from repeat pull-through, not heavy promotion or capex.
Chromium Single Cell 3' Gene Expression reagents
Chromium Single Cell 3' Gene Expression is 10x Genomics, Inc.'s original flagship assay and a clear cash cow: it has broad brand recognition and a large installed base of labs already trained on the platform. In FY2025, 10x Genomics, Inc. reported revenue of about $621 million, and this mature core line helped support recurring reagent demand. The market is more mature now, so this reagent family acts more like a steady cash generator than a growth engine.
Chromium Single Cell Immune Profiling (V(D)J)
Chromium Single Cell Immune Profiling (V(D)J) stays a cash cow because it is a standard assay for immune repertoire studies and keeps driving repeat orders in established labs. Its growth is slower than 10x Genomics, Inc.'s newer spatial products, but the franchise still holds strong share thanks to deep workflow adoption and recurring use. That makes it a steady cash contributor even as newer lines expand faster.
Chromium Single Cell ATAC
Chromium Single Cell ATAC fits Cash Cows: it is a mature epigenomics assay with steady consumables pull from a specialized but durable research base. It likely grows slower than 10x Genomics, Inc.'s newer spatial products, but it still monetizes an installed user base and recurring reagent use. That mix usually means lower growth, but stable, high-margin cash flow.
- Established assay, repeat reagent sales
- Durable niche research demand
- Slower growth than spatial tools
Microfluidic chips, slides, and reagents
Microfluidic chips, slides, and reagents are 10x Genomics, Inc.’s core recurring consumables, so every installed instrument drives repeat pull-through. In FY2024, consumables still made up most revenue, and that mix is what gives this line steady cash-flow support even when capital equipment sales slow.
- Repeat buys from installed base
- High frequency, low ticket, sticky demand
- Supports margins and cash conversion
10x Genomics’ Legacy Cash Engine Keeps the Revenue Stream Flowing
10x Genomics, Inc.'s Cash Cows are the Chromium legacy assays and consumables that keep selling into a large installed base. In FY2025, Company reported about $621 million revenue, with consumables still the main cash engine. These products grow slowly, but they deliver repeat, high-margin pull-through.
| Cash Cow | Why it fits | FY2025 signal |
|---|---|---|
| Chromium assays | Repeat reagent sales | Core of $621m revenue |
Get Your Copy
10x Genomics, Inc. Reference Sources
You're previewing the exact 10x Genomics, Inc. BCG Matrix report you'll receive after purchase. This is the final, fully formatted document—no placeholders, no demo content, and no hidden changes. Once purchased, the same file is delivered for immediate use in analysis, presentation, or strategic planning. What you see here is precisely what you get.
Dogs
Chromium Connect automation system
Chromium Connect is a legacy Chromium-era automation system, and in 2025 it was clearly not a growth focus versus 10x Genomics’ newer single-cell and spatial platforms. Its role is shrinking as customers shift to newer workflows, so its strategic value is limited. In BCG terms, it fits a Dog: low growth, weak pull, and little capital priority.
Legacy Chromium v2 chemistry
Legacy Chromium v2 chemistry fits the Dogs bucket because newer GEM-X single-cell kits have largely replaced it, so demand is shifting away from the older format. In FY2025, 10x Genomics kept pushing the mix toward GEM-X, which leaves v2 with limited pricing power and lower strategic upside. That makes it a classic substitution risk: useful for legacy users, but not a growth driver.
Legacy standalone ATAC workflow
Legacy standalone ATAC is a mature, narrow-use assay, while multiome and newer bundle offers are easier to standardize across labs. In FY2025, that low-growth profile makes it a weak portfolio item: more specialized, less scalable, and less likely to drive share gains for 10x Genomics, Inc.
Older accessory hardware bundles
Older accessory hardware bundles for 10x Genomics, Inc. fit Dogs: they sit around legacy Chromium workflows, add little differentiation, and usually do not create new demand. In 2025, 10x Genomics still tied its platform value to core consumables and new systems, so these add-ons mainly protect the installed base, not expand share.
- Low differentiation
- Limited share gain
- Supports installed customers
- Weak BCG growth profile
Low-volume legacy research kits
Low-volume legacy research kits fit the Dogs bucket because demand is thin, replacement cycles are slow, and newer higher-content assays have already taken the lead. In 10x Genomics, Inc., these kits can still require product support, QC, and field time, but they do not drive meaningful growth or margin expansion.
- Weak demand
- Slow kit replacement
- Higher support burden
- Limited growth upside
10x Genomics Dogs Stayed in the Back Seat in FY2025
Dogs at 10x Genomics, Inc. are legacy Chromium products, older ATAC, and low-volume accessory kits. In FY2025 they stayed tied to the installed base, while newer GEM-X and Multiome systems kept taking mix and attention, so growth, pricing power, and capital priority stayed weak.
| Dog item | FY2025 read |
|---|---|
| Legacy Chromium | Replacement mode |
| Legacy ATAC | Niche demand |
| Accessory kits | Support-only role |
Question Marks
Xenium Prime 5K panels
Xenium Prime 5K sits in a Question Mark slot: high-plex spatial panels target a fast-growing market, but it is still early and crowded. The panel’s 5,000-target scale gives 10x Genomics a strong technical hook, yet buyers are still testing workflows and pricing. 10x must turn pilot use into repeat orders before rivals lock in share.
Xenium protein co-detection workflows
Xenium protein co-detection adds protein readouts to an RNA-first platform, so 10x Genomics can sell into both spatial transcriptomics and spatial proteomics budgets. That widens the addressable market, but adoption is still early, so share and pricing power are not yet settled. With Xenium already used in high-throughput spatial workflows, the protein layer can lift average revenue per system as use cases broaden.
Visium FFPE spatial workflows
Visium FFPE targets the biggest tissue format in translational research, since formalin-fixed paraffin-embedded samples dominate archived pathology use. The workflow is attractive because it lets Company Name tap existing biobank and clinical material, but customer conversion is still early and uneven. It needs more validation, sales support, and workflow training before it can move from a Question Mark to a Star.
Spatial multiomics with immunofluorescence
Spatial multiomics with immunofluorescence links RNA and protein readouts in the same tissue slice, and that makes it a strong fit for high-growth spatial biology. The catch is adoption: workflows are still early, and most labs are in evaluation or pilot use rather than routine buying, so 10x Genomics, Inc. should keep this in Question Mark status.
- Links gene expression and protein signals
- Targets fast-growing tissue research
- Penetration remains early and selective
Biopharma translational spatial programs
Pharma demand for spatial biology is rising fast, but 10x Genomics is still early in many drug-discovery workflows. These biopharma translational spatial programs can scale with broader pharma adoption, yet they are not mature cash generators today. So, they are better viewed as high-upside pipeline bets than steady profit pools.
- Fast-growing pharma interest
- Share still being built
- Scaling, but not cash-rich yet
10x Genomics’ Spatial Bets: Big Growth, Early Proof Needed
Question Marks in 10x Genomics, Inc. are its spatial bets: Xenium Prime 5K, Xenium protein co-detection, Visium FFPE, and spatial multiomics. They sit in fast-growing research markets, but buying is still early and share is not locked in. The 5,000-target panel is a clear hook, yet repeat use must beat rivals and workflow friction.
| Asset | Status | Signal |
|---|---|---|
| Xenium Prime 5K | Question Mark | High plex, early adoption |
| Visium FFPE | Question Mark | Big tissue base, mixed conversion |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.